---
schema_version: "secwatch.filing_event.v1"
accession: "0001576885-24-000096"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:54:18.116298+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Acumen Q3 net loss $29.8M; cash $258.9M; ALTITUDE-AD enrollment on track for H1 2025

## Summary
- Net loss of $29.8M for Q3 2024 vs $13.0M in Q3 2023, driven by higher R&D costs ($27.2M vs $11.2M).
- Cash, equivalents and marketable securities of $258.9M as of Sept 30, 2024, expected to fund operations into H1 2027.
- Phase 2 ALTITUDE-AD enrollment for sabirnetug expected to complete in first half of 2025.
- Topline results from Phase 1 subcutaneous sabirnetug study anticipated in Q1 2025.
- Appointed Amy Schacterle, PhD as Chief Regulatory Officer & Head of Quality in November 2024.

## SEC filing metadata
- accession: 0001576885-24-000096
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000157688524000096/0001576885-24-000096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000157688524000096/abos-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576885-24-000096
- JSON: https://secwatch.observer/filing/0001576885-24-000096.json
- Plain text: https://secwatch.observer/filing/0001576885-24-000096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.